Amolyt Pharma, a Lyon, France and Cambridge, Mass.-based company specialized in developing therapeutic peptides for rare endocrine and related diseases, closed an $80m Series B equity financing round.
The round was co-led by Sectoral Asset Management and Andera Partners, with participation from ATEM Capital, LSP, Novo Holdings (Novo Ventures), Kurma Partners, Mass General Brigham Ventures, Innobio 2 managed by Bpifrance, Orbimed, Pontifax, Eurazeo, Sham Innovation Santé/Turenne Capital and Credit Agricole Creation.
The company plans to use the proceeds from the financing to advance its pipeline of potential therapeutics for rare endocrine and related diseases, including clinical development of AZP-3601 for hypoparathyroidism, pre-clinical development of AZP-3813 for acromegaly and ongoing research related to AZP-3404, and to further expand its early-stage pipeline through both internal research and development activities and potential in-licensing opportunities.
Led by Thierry Abribat, Ph.D., founder, and chief executive officer, Amolyt Pharma is a clinical stage biotechnology company advancing therapeutic peptides to deliver life-changing treatments to patients suffering from rare endocrine and related diseases. Its portfolio includes:
- AZP-3601, a long-acting PTH analog as a potential treatment of hypoparathyroidism,
- AZP-3813, a macrocyclic peptide growth hormone receptor antagonist for the potential treatment of acromegaly, and
- AZP-3404, which is undergoing indication selection work.